Compare
Alpha Tau Medical Ltd. vs NeuroPace Inc vs CVRx, Inc. vs Iradimed Corp
| Latest fiscal year | Alpha Tau Medical Ltd. DRTS | NeuroPace Inc NPCE | CVRx, Inc. CVRX | Iradimed Corp IRMD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $99.99M | $56.65M | $83.81M |
| Revenue growth (YoY) | n/a | +25.1% | +10.4% | +14.4% |
| Gross margin | n/a | 77.2% | 85.3% | 76.7% |
| Operating margin | n/a | -16.3% | -90.5% | 31.2% |
| Net margin | n/a | -21.5% | -94.1% | 26.8% |
| Net income | -$42.63M | -$21.46M | -$53.31M | $22.48M |
| EPS (Diluted) | -$0.53 | -$0.66 | -$2.04 | $1.75 |
| Operating cash flow | -$26.68M | -$11.01M | -$40.17M | $24.95M |
| Free cash flow | -$32.76M | -$11.34M | -$40.75M | $17.18M |
| Cash & equivalents | $12.20M | $21.69M | $75.71M | $51.16M |
| Total assets | $105.65M | $105.56M | $104.79M | $108.78M |
| Total liabilities | $28.55M | $86.53M | $65.47M | $14.16M |
| Shareholders' equity | $77.10M | $19.03M | $39.32M | $94.62M |
| Return on year-end equity | -55.3% | -112.8% | -135.6% | 23.8% |
| Shares outstanding | 88.01M | 33.57M | 26.31M | 12.78M |
Revenue, most recent five fiscal years
| Fiscal year | Alpha Tau Medical Ltd. | NeuroPace Inc | CVRx, Inc. | Iradimed Corp |
|---|---|---|---|---|
| Latest | n/a | $99.99M Ended 2025-12-31 | $56.65M Ended 2025-12-31 | $83.81M Ended 2025-12-31 |
| 1 year earlier | n/a | $79.91M Ended 2024-12-31 | $51.29M Ended 2024-12-31 | $73.24M Ended 2024-12-31 |
| 2 years earlier | n/a | $65.42M Ended 2023-12-31 | $39.30M Ended 2023-12-31 | $65.56M Ended 2023-12-31 |
| 3 years earlier | n/a | $45.52M Ended 2022-12-31 | $22.47M Ended 2022-12-31 | $53.30M Ended 2022-12-31 |
| 4 years earlier | n/a | $45.18M Ended 2021-12-31 | $13.04M Ended 2021-12-31 | $41.81M Ended 2021-12-31 |